126 results
Page 4 of 7
6-K
EX-99.1
ylyd30 3uq
23 Feb 15
Live Filing
12:00am
6-K
EX-99.1
qj08ri
18 Nov 14
Live Filing
12:00am
6-K
EX-99.1
7iyl4aas3qrickiz
7 Nov 14
Live Filing
12:00am
6-K
EX-99.1
nkxo4c
8 Sep 14
Successful Completion of Phase Iii Program for Teva’s Reslizumab
12:00am
6-K
EX-99.1
icp846 1aaf
2 Sep 14
Live Filing
12:00am
6-K
EX-99.1
7ugmvxy4
14 Jul 14
First Breath-Actuated Dry-Powder SABA Inhaler to be Accepted by FDA for Review
12:00am
6-K
w6y0vbaz vhp3ko1e2ld
18 Jun 14
Current report (foreign)
12:00am
6-K
EX-99.1
lh33wvt2hz9xgiqsz06
9 Jun 14
FDA Approves Expanded Label for AZILECT® for Treatment Across All Stages of Parkinson’s Disease
12:00am
6-K
EX-99.1
x6re02opoaip
24 Apr 14
Pride-hd Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
12:00am
6-K
EX-99.1
nungvszlu 8et9uk
3 Mar 14
The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
12:00am
6-K
gn69mrf
17 Jan 14
Current report (foreign)
12:00am
6-K
EX-99.1
uckrbmtwy
27 Nov 13
Teva Announces Additional Regulatory Exclusivity for Treanda® (Bendamustine Hci) for Injection
12:00am
6-K
EX-99.1
lwaehyodz7fv6z
18 Nov 13
Teva Announces Updates to Oncology Biologic Portfolio
12:00am
6-K
EX-99.1
pm1788aqn vnq2knudi
23 Sep 13
Teva Announces Favorable Court Ruling In Azilect® Patent Infringement Litigation Against Mylan
12:00am
6-K
EX-99.1
5v101i ix
17 Sep 13
Fda Approves Teva’s Treanda® (Bendamustine Hci) Injection, a New Liquid Formulation
12:00am
6-K
EX-32.1
k3cw2y42fg9afc8c
12 Jun 13
Live Filing
12:00am
6-K
EX-99.1
5bfxdb8pix
8 May 13
Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder
12:00am
6-K
EX-32.1
bwcptjwx2ls
6 May 13
Live Filing
12:00am